Calidi Biotherapeutics (NYSE American: CLDI) has earned FDA Fast Track designation for CLD-201 (SuperNova), its first-in-class stem-cell loaded oncolytic virus therapy for soft tissue sarcoma—advancing a promising new approach for hard-to-treat solid tumors. With IND clearance already in hand, Calidi is set to launch a Phase 1 trial targeting sarcoma and other high-need cancers, accelerating its path toward potential priority review and expedited approval.

Alliance Entertainment (Nasdaq: AENT) has promoted seven seasoned executives to Senior Vice President roles, reinforcing its leadership bench as it scales operations across collectibles, exclusive content, and global distribution. With deep expertise across finance, IT, international sales, and legal affairs, these leaders are poised to accelerate Alliance’s capital-light growth model and margin expansion in the fast-evolving entertainment and pop culture ecosystem.

Lantern Pharma (Nasdaq: LTRN) has completed Japanese enrollment ahead of schedule in its Phase 2 HARMONIC™ trial for LP-300, targeting never-smoker NSCLC—a $4B global market with no approved therapies. This key milestone accelerates data generation across U.S. and Asian cohorts as Lantern positions LP-300 to address a significant unmet need in lung cancer treatment.

FibroBiologics (Nasdaq: FBLG) reported Q2 2025 results and highlighted strong R&D momentum, including preclinical success in psoriasis and preparation for a Phase 1/2 DFU trial in early 2026. Backed by a $25M financing agreement and over 275 issued/pending patents, the company is leveraging its fibroblast-based platform to target chronic disease markets with high unmet need.